<DOC>
	<DOC>NCT00305539</DOC>
	<brief_summary>Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.</brief_summary>
	<brief_title>HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis</brief_title>
	<detailed_description>The protocol consists of a SC injection of adalimumab or placebo every 2 weeks for 10 weeks added to steroids</detailed_description>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Age â‰¥ 50 years ACR criteria for Giant cell arteritis (HUNDER 1990) Positive Temporal artery biopsy Plus standard inclusion criteria for Humira protocols Prednisone treatment for a different disease at a dose &gt;15 mg/day Corticoid treatment for GCA more than 10 days GCA treatment with prednisone &gt; 1 mg/kg whatever period of time GCA treatment with an antiTNF, MTX, cyclosporine, cyclophosphamide, dapsone or steroid bolus Recent, permanent or transient visual loss due to GCA and the presence of any specific visual abnormality (diplopia, hallucination) Plus standard exclusion criteria for Humira protocols</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Giant Cell Arteritis</keyword>
	<keyword>Placebo</keyword>
	<keyword>Anti-TNF</keyword>
	<keyword>Multicenter-randomized-trial</keyword>
	<keyword>Proved GCA according to ACR criteria (HUNDER et al 1990)</keyword>
</DOC>